David Eidelberg

List of Publications by Year
in descending order

222 papers	17,362 citations	11608 70 h-index	15218 126 g-index
226 all docs	226 docs citations	226 times ranked	11332 citing authors

#	Article	IF	Citations
1	Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease. New England Journal of Medicine, 2001, 344, 710-719.	13.9	2,253
2	Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet, The, 2007, 369, 2097-2105.	6.3	949
3	Inferior Parietal Lobule. Archives of Neurology, 1984, 41, 843.	4.9	366
4	Changes in network activity with the progression of Parkinson's disease. Brain, 2007, 130, 1834-1846.	3.7	360
5	Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends in Neurosciences, 2009, 32, 548-557.	4.2	347
6	Patterns of regional brain activation associated with different forms of motor learning. Brain Research, 2000, 871, 127-145.	1.1	344
7	Network modulation in the treatment of Parkinson's disease. Brain, 2006, 129, 2667-2678.	3.7	324
8	Metabolic brain networks associated with cognitive function in Parkinson's disease. NeuroImage, 2007, 34, 714-723.	2.1	309
9	Functional brain networks in DYT1 dystonia. Annals of Neurology, 1998, 44, 303-312.	2.8	302
10	Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurology, The, 2010, 9, 149-158.	4.9	291
11	Abnormal Metabolic Network Activity in Parkinson'S Disease: Testâ€"Retest Reproducibility. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 597-605.	2.4	290
12	Cerebellothalamocortical Connectivity Regulates Penetrance in Dystonia. Journal of Neuroscience, 2009, 29, 9740-9747.	1.7	279
13	Increased anterior cingulate and caudate activity in bipolar mania. Biological Psychiatry, 2000, 48, 1045-1052.	0.7	258
14	Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Annals of Neurology, 2002, 52, 628-634.	2.8	252
15	Parkinson's disease tremor-related metabolic network: Characterization, progression, and treatment effects. NeuroImage, 2011, 54, 1244-1253.	2.1	216
16	Differential Cortical and Subcortical Activations in Learning Rotations and Gains for Reaching: A PET Study. Journal of Neurophysiology, 2004, 91, 924-933.	0.9	215
17	Impaired sequence learning in carriers of the DYT1 dystonia mutation. Annals of Neurology, 2003, 54, 102-109.	2.8	189
18	Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217.	4.5	185

#	Article	IF	Citations
19	Current Opinions and Areas of Consensus on the Role of the Cerebellum in Dystonia. Cerebellum, 2017, 16, 577-594.	1.4	184
20	Positron emission tomographic studies in restless legs syndrome. Movement Disorders, 1999, 14, 141-145.	2.2	177
21	Abnormalities in Metabolic Network Activity Precede the Onset of Motor Symptoms in Parkinson's Disease. Journal of Neuroscience, 2010, 30, 1049-1056.	1.7	175
22	Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19559-19564.	3.3	169
23	Abnormal metabolic networks in atypical parkinsonism. Movement Disorders, 2008, 23, 727-733.	2.2	168
24	Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and ¹⁸F-FDOPA PET Outcomes. Journal of Nuclear Medicine, 2010, 51, 7-15.	2.8	164
25	Hereditary dystonia as a neurodevelopmental circuit disorder: Evidence from neuroimaging. Neurobiology of Disease, 2011, 42, 202-209.	2.1	159
26	Scaled subprofile modeling of resting state imaging data in Parkinson's disease: Methodological issues. NeuroImage, 2011, 54, 2899-2914.	2.1	152
27	Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. NeuroImage, 2006, 31, 301-307.	2.1	151
28	Abnormal metabolic network activity in REM sleep behavior disorder. Neurology, 2014, 82, 620-627.	1.5	151
29	Relationships Among the Metabolic Patterns That Correlate With Mnemonic, Visuospatial, and Mood Symptoms in Parkinsonâ€™s Disease. American Journal of Psychiatry, 2002, 159, 746-754.	4.0	147
30	Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurology, The, 2007, 6, 926-932.	4.9	145
31	Microstructural white matter changes in carriers of the DYT1 gene mutation. Annals of Neurology, 2004, 56, 283-286.	2.8	137
32	Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease. Journal of Neuroscience, 2008, 28, 4201-4209.	1.7	135
33	Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain, 2014, 137, 3122-3128.	3.7	134
34	Metabolic brain networks in translational neurology: Concepts and applications. Annals of Neurology, 2012, 72, 635-647.	2.8	130
35	Symmetry and Asymmetry in the Human Posterior Thalamus. Archives of Neurology, 1982, 39, 325.	4.9	128
36	[11C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length. Annals of Neurology, 1998, 43, 253-255.	2.8	120

#	Article	IF	Citations
37	Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 501-509.	2.4	120
38	Network imaging biomarkers: insights and clinical applications in Parkinson's disease. Lancet Neurology, The, 2018, 17, 629-640.	4.9	120
39	Primary dystonia: Is abnormal functional brain architecture linked to genotype?. Annals of Neurology, 2002, 52, 853-856.	2.8	119
40	Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6638-6643.	3.3	112
41	The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinsonâ€™s disease. Cell Metabolism, 2022, 34, 396-407.e6.	7.2	111
42	A New Approach to Spatial Covariance Modeling of Functional Brain Imaging Data: Ordinal Trend Analysis. Neural Computation, 2005, 17, 1602-1645.	1.3	109
43	Functional correlates of pallidal stimulation for Parkinson's disease. Annals of Neurology, 2001, 49, 155-164.	2.8	107
44	The differential effect of PD and normal aging on early explicit sequence learning. Neurology, 2003, 60, 1313-1319.	1.5	107
45	Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. NeuroImage, 2004, 21, 1497-1507.	2.1	107
46	Learning and consolidation of visuo-motor adaptation in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 6-11.	1.1	107
47	Preclinical Huntington's disease: Compensatory brain responses during learning. Annals of Neurology, 2006, 59, 53-59.	2.8	106
48	Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Movement Disorders, 1998, 13, 268-274.	2.2	105
49	Microstructural white matter changes in primary torsion dystonia. Movement Disorders, 2008, 23, 234-239.	2.2	103
50	A disease-specific metabolic brain network associated with corticobasal degeneration. Brain, 2014, 137, 3036-3046.	3.7	103
51	Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. NeuroImage, 2009, 45, 1241-1252.	2.1	102
52	Functional brain networks and abnormal connectivity in the movement disorders. NeuroImage, 2012, 62, 2261-2270.	2.1	100
53	Increased cerebellar activation during sequence learning in DYT1 carriers: an equiperformance study. Brain, 2007, 131, 146-154.	3.7	99
54	Executive processes in Parkinson's disease: FDG-PET and network analysis. Human Brain Mapping, 2004, 22, 236-245.	1.9	95

#	Article	IF	Citations
55	Metabolic network as a progression biomarker of premanifest Huntingtonâ€™s disease. Journal of Clinical Investigation, 2013, 123, 4076-4088.	3.9	91
56	Parkinson's Disease Spatial Covariance Pattern: Noninvasive Quantification with Perfusion MRI. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 505-509.	2.4	90
57	Metabolic changes following subthalamotomy for advanced Parkinson's disease. Annals of Neurology, 2001, 50, 514-520.	2.8	89
58	Metabolic resting-state brain networks in health and disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2563-2568.	3.3	89
59	Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study. Brain, 2010, 133, 690-700.	3.7	88
60	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	2.2	88
61	Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Movement Disorders, 2002, 17, 1265-1270.	2.2	86
62	Parkinson's disease cognitive network correlates with caudate dopamine. NeuroImage, 2013, 78, 204-209.	2.1	83
63	Automated Differential Diagnosis of Early Parkinsonism Using Metabolic Brain Networks: A Validation Study. Journal of Nuclear Medicine, 2016, 57, 60-66.	2.8	83
64	Imaging essential tremor. Movement Disorders, 2010, 25, 679-686.	2.2	80
65	Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain, 2008, 131, 1373-1380.	3.7	75
66	Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Annals of Neurology, 2001, 50, 181-187.	2.8	74
67	Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. Neurology, 2016, 87, 1925-1933.	1.5	74
68	Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinsonâ€™s disease. JCI Insight, 2017, 2, e90133.	2.3	74
69	Learning networks in health and Parkinson's disease: Reproducibility and treatment effects. Human Brain Mapping, 2003, 19, 197-211.	1.9	72
70	Quantification of Parkinsonâ€™s disease-related network expression with ECD SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 496-501.	3.3	72
71	Dopaminergic correlates of metabolic network activity in Parkinson's disease. Human Brain Mapping, 2015, 36, 3575-3585.	1.9	71
72	Impaired sequence learning in dystonia mutation carriers: a genotypic effect. Brain, 2011, 134, 1416-1427.	3.7	70

#	Article	IF	Citations
73	Brain networks in Huntington disease. Journal of Clinical Investigation, 2011, 121, 484-492.	3.9	69
74	Neuroimaging and therapeutics in movement disorders. NeuroRx, 2005, 2, 361-371.	6.0	67
75	Dopaminergic Suppression of Brain Deactivation Responses during Sequence Learning. Journal of Neuroscience, 2008, 28, 10687-10695.	1.7	65
76	Network modulation following sham surgery in Parkinsonâ€™s disease. Journal of Clinical Investigation, 2014, 124, 3656-3666.	3.9	65
77	Functional Neuroimaging in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009274-a009274.	2.9	64
78	Imaging markers of mild cognitive impairment: Multivariate analysis of CBF SPECT. Neurobiology of Aging, 2007, 28, 1062-1069.	1.5	63
79	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	1.5	63
80	Parkinson's disease-related network topographies characterized with resting state functional MRI. Human Brain Mapping, 2017, 38, 617-630.	1.9	62
81	Assessing Cerebral Glucose Metabolism in Patients with Idiopathic Rapid Eye Movement Sleep Behavior Disorder. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 2062-2069.	2.4	61
82	The metabolic pathology of dopa-responsive dystonia. Annals of Neurology, 2005, 57, 596-600.	2.8	60
83	Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. Journal of Neurosurgery, 2009, 110, 1278-1282.	0.9	59
84	Metabolic changes in DYT11 myoclonus-dystonia. Neurology, 2013, 80, 385-391.	1.5	58
85	Gene therapy reduces Parkinsonâ€™s disease symptoms by reorganizing functional brain connectivity. Science Translational Medicine, 2018, 10, .	5.8	58
86	Improved Sequence Learning with Subthalamic Nucleus Deep Brain Stimulation: Evidence for Treatment-Specific Network Modulation. Journal of Neuroscience, 2012, 32, 2804-2813.	1.7	57
87	Functional brain networks in movement disorders. Current Opinion in Neurology, 1998, 11, 319-326.	1.8	57
88	Abnormal metabolic brain network associated with Parkinsonâ€™s disease: replication on a new European sample. Neuroradiology, 2017, 59, 507-515.	1.1	55
89	<scp>GBA</scp> Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes. Movement Disorders, 2020, 35, 2201-2210.	2.2	55
90	Metabolic Imaging of Bilateral Anterior Capsulotomy in Refractory Obsessive Compulsive Disorder: an FDG PET Study. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 880-887.	2.4	53

#	Article	IF	Citations
91	Functional Imaging of Cerebral Blood Flow and Glucose Metabolism in Parkinsonâ€™s Disease and Huntingtonâ€™s Disease. Molecular Imaging and Biology, 2007, 9, 223-233.	1.3	52
92	Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 683-693.	2.4	51
93	Principal Components Analysis of Brain Metabolism Predicts Development of Alzheimer Dementia. Journal of Nuclear Medicine, 2019, 60, 837-843.	2.8	50
94	Pallidal stimulation for Parkinsonism: Improved brain activation during sequence learning. Annals of Neurology, 2002, 52, 144-152.	2.8	49
95	The Age-Related Perfusion Pattern Measured With Arterial Spin Labeling MRI in Healthy Subjects. Frontiers in Aging Neuroscience, 2018, 10, 214.	1.7	49
96	Abnormal regional brain function in Parkinson's disease: truth or fiction?. NeuroImage, 2009, 45, 260-266.	2.1	48
97	Neuroimaging in human dystonia. Journal of Medical Investigation, 2005, 52, 272-279.	0.2	47
98	Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging. Movement Disorders, 2007, 22, 167-173.	2.2	46
99	Early Parkinson's disease: Longitudinal changes in brain activity during sequence learning. Neurobiology of Disease, 2010, 37, 455-460.	2.1	46
100	Abnormal Metabolic Pattern Associated with Cognitive Impairment in Parkinson'S Disease: A Validation Study. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1478-1484.	2.4	46
101	Knowledge gaps and research recommendations for essential tremor. Parkinsonism and Related Disorders, 2016, 33, 27-35.	1.1	46
102	Quantitative Brain PET Comparison of 2D and 3D Acquisitions on the GE Advance Scanner. Molecular Imaging and Biology, 1998, 1, 135-144.	0.3	45
103	L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, 146-151.	1.1	45
104	Functional brain imaging of cognitive dysfunction in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 963-969.	0.9	43
105	Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data. Journal of Visualized Experiments, 2013, , .	0.2	43
106	Parkinson's Diseaseâ€”Related Spatial Covariance Pattern Identified with Resting-State Functional MRI. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1764-1770.	2.4	43
107	Dyskinesia Matters. Movement Disorders, 2020, 35, 392-396.	2.2	42
108	Characterization of diseaseâ€related covariance topographies with SSMPCA toolbox: Effects of spatial normalization and PET scanners. Human Brain Mapping, 2014, 35, 1801-1814.	1.9	41

#	Article	IF	Citations
109	Early stage Parkinson's disease patients and normal volunteers: Comparative mechanisms of sequence learning. Human Brain Mapping, 2003, 20, 246-258.	1.9	40
110	Network Structure and Function in Parkinsonâ€™s Disease. Cerebral Cortex, 2018, 28, 1-15.	1.6	39
111	Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease. Movement Disorders, 2009, 24, S725-31.	2.2	37
112	Thalamocortical Connectivity Correlates with Phenotypic Variability in Dystonia. Cerebral Cortex, 2015, 25, 3086-3094.	1.6	37
113	Effects of levodopa on regional cerebral metabolism and blood flow. Movement Disorders, 2015, 30, 54-63.	2.2	37
114	Modulation of regional brain function by deep brain stimulation: studies with positron emission tomography. Current Opinion in Neurology, 2002, 15, 451-455.	1.8	36
115	18F-Fluorodeoxyglucose PET in the Evaluation of Parkinson Disease. PET Clinics, 2010, 5, 55-64.	1.5	36
116	LRRK2 and GBA Variants Exert Distinct Influences on Parkinsonâ€™s Disease-Specific Metabolic Networks. Cerebral Cortex, 2020, 30, 2867-2878.	1.6	35
117	Parkinson's Disease: Increased Motor Network Activity in the Absence of Movement. Journal of Neuroscience, 2013, 33, 4540-4549.	1.7	34
118	Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinsonâ€™s disease. Neuroscience Bulletin, 2014, 30, 823-837.	1.5	34
119	Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Science and Medicine, 2015, 2, e000074-e000074.	1.1	34
120	Functional brain networks in Parkinson's disease. Parkinsonism and Related Disorders, 2001, 8, 91-94.	1.1	33
121	Correlates of movement initiation and velocity in Parkinson's disease: A longitudinal PET study. NeuroImage, 2007, 34, 361-370.	2.1	33
122	Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiology of Disease, 2009, 35, 141-147.	2.1	32
123	Abnormal Metabolic Brain Networks in a Nonhuman Primate Model of Parkinsonism. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 633-642.	2.4	32
124	Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: Multivariate and univariate analyses in American and Chinese patient cohorts. Human Brain Mapping, 2018, 39, 2842-2858.	1.9	32
125	Evolving metabolic changes during the first postoperative year after subthalamotomy. Journal of Neurosurgery, 2003, 99, 872-878.	0.9	31
126	Functional brain networks in movement disorders. Current Opinion in Neurology, 2012, 25, 392-401.	1.8	31

#	Article	IF	Citations
127	Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. Scientific Reports, 2017, 7, 16005.	1.6	30
128	Predictive Value of ¹⁸F-Florbetapir and ¹⁸F-FDG PET for Conversion from Mild Cognitive Impairment to Alzheimer Dementia. Journal of Nuclear Medicine, 2020, 61, 597-603.	2.8	30
129	Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia. JCI Insight, 2016, 1, e86615.	2.3	28
130	Abnormal metabolic brain networks in Parkinsonâ€™s disease. Progress in Brain Research, 2010, 184, 160-176.	0.9	26
131	Quantifying Significance of Topographical Similarities of Disease-Related Brain Metabolic Patterns. PLoS ONE, 2014, 9, e88119.	1.1	26
132	The Utility of Neuroimaging in the Differential Diagnosis of Parkinsonian Syndromes. Seminars in Neurology, 2014, 34, 202-209.	0.5	26
133	Waht is it? Case 1, 1990: Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. Movement Disorders, 1990, 5, 341-351.	2.2	24
134	Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. Neurology, 2020, 94, e774-e784.	1.5	24
135	Visualizing the evolution of abnormal metabolic networks in the brain using PET. Computerized Medical Imaging and Graphics, 1995, 19, 295-306.	3.5	23
136	Regional Brain Metabolism in a Murine Systemic Lupus Erythematosus Model. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1315-1320.	2.4	23
137	The effect of 18F-FDG-PET image reconstruction algorithms on the expression of characteristic metabolic brain network in Parkinsonâ€™s disease. Physica Medica, 2017, 41, 129-135.	0.4	23
138	Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patternsâ€™ based approach. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2901-2910.	3.3	23
139	Brain stimulation and functional imaging with fMRI and PET. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 77-95.	1.0	22
140	Asymmetric predominantly ipsilateral blepharospasm and contralateral parkinsonism in an elderly patient with a right mesencephalic cyst. Movement Disorders, 1998, 13, 135-139.	2.2	21
141	Switching Language Modes: Complementary Brain Patterns for Formulaic and Propositional Language. Brain Connectivity, 2018, 8, 189-196.	0.8	21
142	The relationship between fasting serum glucose and cerebral glucose metabolism in late-life depression and normal aging. Psychiatry Research - Neuroimaging, 2014, 222, 84-90.	0.9	20
143	A multivariate metabolic imaging marker for behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 583-594.	1.2	20
144	Metabolic Network Abnormalities in Drugâ€NaÃ¯ve Parkinson's Disease. Movement Disorders, 2020, 35, 587-594.	2.2	19

#	Article	IF	Citations
145	Dynamic ¹⁸F-FPCIT PET: Quantification of Parkinson Disease Metabolic Networks and Nigrostriatal Dopaminergic Dysfunction in a Single Imaging Session. Journal of Nuclear Medicine, 2021, 62, 1775-1782.	2.8	19
146	Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. Movement Disorders, 2015, 30, 1283-1288.	2.2	18
147	Modulation of Abnormal Metabolic Brain Networks by Experimental Therapies in a Nonhuman Primate Model of Parkinson Disease: An Application to Human Retinal Pigment Epithelial Cell Implantation. Journal of Nuclear Medicine, 2016, 57, 1591-1598.	2.8	18
148	Spectral guided sparse inverse covariance estimation of metabolic networks in Parkinson's disease. NeuroImage, 2021, 226, 117568.	2.1	18
149	Cognition-Related Functional Topographies in Parkinsonâ€™s Disease: Localized Loss of the Ventral Default Mode Network. Cerebral Cortex, 2021, 31, 5139-5150.	1.6	18
150	Gene transfer therapy for neurodegenerative disorders. Movement Disorders, 2007, 22, 1223-1228.	2.2	16
151	Understanding the Anatomy of Dystonia: Determinants of Penetrance and Phenotype. Current Neurology and Neuroscience Reports, 2013, 13, 401.	2.0	16
152	The visual perception of natural motion: abnormal task-related neural activity in DYT1 dystonia. Brain, 2015, 138, 3598-3609.	3.7	16
153	Dopamine cell transplantation in Parkinson's disease: challenge and perspective. British Medical Bulletin, 2011, 100, 173-189.	2.7	15
154	Using imaging to identify psychogenic parkinsonism before deep brain stimulation surgery. Journal of Neurosurgery, 2012, 116, 114-118.	0.9	15
155	Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia. JCI Insight, 2017, 2, .	2.3	15
156	Abnormal network topographies and changes in global activity: Absence of a causal relationship. NeuroImage, 2012, 63, 1827-1832.	2.1	14
157	18FDG-microPET and MR DTI findings in Tor1a+/â^’ heterozygous knock-out mice. Neurobiology of Disease, 2015, 73, 399-406.	2.1	14
158	Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model. Neurobiology of Disease, 2016, 96, 31-37.	2.1	13
159	Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimerâ€™s disease topography. NeuroImage: Clinical, 2022, 35, 103080.	1.4	13
160	Identification and validation of Alzheimerâ€™s disease-related metabolic brain pattern in biomarker confirmed Alzheimerâ€™s dementia patients. Scientific Reports, 2022, 12, .	1.6	13
161	Reproducible metabolic topographies associated with multiple system atrophy: Network and regional analyses in Chinese and American patient cohorts. NeuroImage: Clinical, 2020, 28, 102416.	1.4	12
162	Early registration of diffusion tensor images for group tractography of dystonia patients. Journal of Magnetic Resonance Imaging, 2013, 37, 67-75.	1.9	11

#	Article	IF	Citations
163	Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance. Lupus Science and Medicine, 2019, 6, e000327.	1.1	11
164	Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration. Neurology, 2021, 96, e1358-e1368.	1.5	11
165	In utero exposure to maternal antiâ€“aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring. Science Translational Medicine, 2022, 14, eabe9726.	5.8	11
166	The assessment of neurological systems with functional imaging. Brain and Language, 2007, 102, 192-199.	0.8	10
167	Human Radiation Dosimetry for the N-Methyl-d-Aspartate Receptor Radioligand ¹¹C-CNS5161. Journal of Nuclear Medicine, 2015, 56, 869-872.	2.8	10
168	Imbalance of the direct and indirect pathways in focal dystonia: a balanced view. Brain, 2017, 140, 3075-3077.	3.7	10
169	The effects of image reconstruction algorithms on topographic characteristics, diagnostic performance and clinical correlation of metabolic brain networks in Parkinsonâ€™s disease. Physica Medica, 2018, 52, 104-112.	0.4	10
170	Milestones in neuroimaging. Movement Disorders, 2011, 26, 868-978.	2.2	9
171	Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3522-3529.	3.3	9
172	Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy. Physica Medica, 2022, 98, 131-138.	0.4	9
173	Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease. Lancet Neurology, The, 2019, 18, 713-714.	4.9	8
174	Parkinson's disease-related pattern (PDRP) identified using resting-state functional MRI: Validation study. NeuroImage Reports, 2021, 1, 100026.	0.5	8
175	Hemispheric Network Expression in Parkinsonâ€™s Disease: Relationship to Dopaminergic Asymmetries. Journal of Parkinson's Disease, 2020, 10, 1737-1749.	1.5	8
176	A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism. Scientific Reports, 2022, 12, 2763.	1.6	8
177	Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease. Movement Disorders, 2006, 21, 549-555.	2.2	7
178	White matter changes in primary dystonia determined by 2D distribution analysis of diffusion tensor images. Journal of Magnetic Resonance Imaging, 2013, 37, 59-66.	1.9	7
179	Dopamine modulates striatal response to reward and punishment in patients with Parkinsonâ€™s disease. NeuroReport, 2018, 29, 532-540.	0.6	7
180	PET Imaging in Parkinson's Disease and Other Neurodegenerative Disorders. , 2007, , 821-828.		7

#	Article	IF	Citations
181	Adaptive and pathological connectivity responses in Parkinsonâ€™s disease brain networks. Cerebral Cortex, 2023, 33, 917-932.	1.6	7
182	Three-fold cross-validation of parkinsonian brain patterns. , 2010, 2010, 2906-9.		6
183	Network Imaging in Parkinsonian and Other Movement Disorders: Network Dysfunction and Clinical Correlates. International Review of Neurobiology, 2019, 144, 143-184.	0.9	6
184	Bloodâ€“brain barrier permeability in Parkinsonâ€™s disease patients with and without dyskinesia. Journal of Neurology, 2021, 268, 2246-2255.	1.8	6
185	Neuroimaging evaluation of deep brain stimulation in the treatment of representative neurodegenerative and neuropsychiatric disorders. Bioelectronic Medicine, 2021, 7, 4.	1.0	6
186	Analysis of the time course of COVID-19 cases and deaths from countries with extensive testing allows accurate early estimates of the age specific symptomatic CFR values. PLoS ONE, 2021, 16, e0253843.	1.1	6
187	Assessment of disease progression in parkinsonism. Journal of Neurology, 2004, 251, vii4-vii8.	1.8	5
188	Graph Theory-Guided Transcranial Magnetic Stimulation in Neurodegenerative Disorders. Bioelectronic Medicine, 2014, 1, 15-18.	1.0	5
189	Longitudinal Changes in the Motor Learning-Related Brain Activation Response in Presymptomatic Huntington's Disease. PLoS ONE, 2016, 11, e0154742.	1.1	5
190	Title is missing!. Current Opinion in Neurology, 2003, 16, 471-474.	1.8	4
191	New Strategies for Automated Differential Diagnosis of Degenerative Brain Disorders. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 3421-5.	0.5	4
192	Different Î²-amyloid binding patterns in Alzheimer and Parkinson diseases. Neurology, 2013, 81, 516-517.	1.5	4
193	Disruption of network for visual perception of natural motion in primary dystonia. Human Brain Mapping, 2018, 39, 1163-1174.	1.9	4
194	Atypical clinical presentation of pathologically proven Parkinson's disease: The role of Parkinson's disease related metabolic pattern. Parkinsonism and Related Disorders, 2020, 78, 1-3.	1.1	4
195	Stimulation of the Subthalamic Nucleus Changes Cortical-Subcortical Blood Flow Patterns During Speech: A Positron Emission Tomography Study. Frontiers in Neurology, 2021, 12, 684596.	1.1	4
196	Metabolic Networks in Parkinsonâ€™s Disease. , 2013, , 403-415.		3
197	Positron Emission Tomography and Embryonic Dopamine Cell Transplantation in Parkinsonâ€™s Disease. , 2005, , 45-57.		3
198	Prospective F-18 FDOPA PET Imaging Study in Human PD. Nuclear Medicine and Molecular Imaging, 0, , 1.	0.6	3

#	Article	IF	Citations
199	Radiation Absorbed Dose to the Basal Ganglia from Dopamine Transporter Radioligand¹⁸F-FPCIT. BioMed Research International, 2014, 2014, 1-5.	0.9	2
200	Radiomics and supervised machine learning in the diagnosis of parkinsonism with FDG PET: promises and challenges. Annals of Translational Medicine, 2020, 8, 808-808.	0.7	2
201	PET Imaging in Parkinsons Disease. Current Medical Imaging, 2007, 3, 233-241.	0.4	1
202	Multivariate analysis: Applications to the study of hereditary movement disorders. Clinical Neuroscience Research, 2007, 6, 375-380.	0.8	1
203	IC-P-078: Correlation between metabolic and CSF biomarkers in Alzheimer's disease patients with early cognitive decline. , 2015, 11, P56-P57.		1
204	Editorial: introducing the new Co-Editors-in-Chief of Current Opinion in Neurology. Current Opinion in Neurology, 2017, 30, 207.	1.8	1
205	[P1â€“391]: MONITORING THE PROGRESSION OF DEMENTIA USING FGDâ€PET BRAIN IMAGING AND NETWORK ANALYSIS: ROLE OF THE ALZHEIMER's DISEASEâ€RELATED PATTERN. Alzheimer's and Dementia, 2017, 13, P416.	0.4	1
206	Functional imaging in Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 263-287.	1.0	1
207	PET and SPECT Imaging in Parkinsonian Syndromes. , 2014, , 619-638.		1
208	PET Applications to Surgical Treatment of Parkinson's Disease. Loss,grief & Care, 2000, 8, 55-57.	0.2	0
209	Positron Emission Tomography Imaging. Frontiers of Neurology and Neuroscience, 2009, 25, 197-202.	3.0	0
210	P3-152: Correlation between metabolic and CSF biomarkers in Alzheimer's disease patients with early cognitive decline. , 2015, 11, P685-P686.		0
211	Functional Imaging to Study Movement Disorders. , 2015, , 201-212.		0
212	Parkinsonian differentiation using PCA image correlation scores. , 2015, , .		0
213	Brain Network Metabolic Changes in Patients with Parkinsonian Tremors. , 0, , .		0
214	[ICâ€Pâ€035]: MONITORING THE PROGRESSION OF DEMENTIA USING FDGâ€PET BRAIN IMAGING AND NETWORK ANALYSIS: ROLE OF THE ALZHEIMER's DISEASEâ€RELATED PATTERN. Alzheimer's and Dementia, 2017, 13, P31.	0.4	0
215	ICâ€Pâ€045: SIMILAR METABOLIC BRAIN CHARACTERISTICS OF DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P45.	0.4	0
216	ICâ€Pâ€073: ABNORMAL METABOLIC NETWORK ACTIVITY IN PARKINSON'S DISEASE WITH GBA VARIANTS. Alzheimer's and Dementia, 2018, 14, P65.	0.4	0

#	Article	IF	Citations
217	Visualizing Network Connectivity in Parkinson'S Disease. , 2018, , .		0
218	P3â€364: SIMILAR METABOLIC BRAIN CHARACTERISTICS OF DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1227.	0.4	0
219	Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. Movement Disorders, 2020, 35, 901-901.	2.2	0
220	Use of positron-emission tomography as a diagnostic and differential diagnostic tool in parkinsonian syndromes. , 2020, , 313-329.		0
221	Neuroimaging and therapeutics in movement disorders. Neurotherapeutics, 2005, 2, 361-371.	2.1	0
222	PET and SPECT Imaging in Atypical Parkinsonian Syndromes. , 2021, , 729-757.		0